{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:02:04Z","timestamp":1784685724368,"version":"3.55.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with TP53 mutant mantle cell lymphoma (MCL) face poor chemotherapy response and early progression, requiring novel therapies. Nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting nicotinamide adenine dinucleotide salvage enzyme overexpressed in MCL cell lines and patient tissues, emerges as a therapeutic target. The NAMPT inhibitor KPT-9274 reduced viability and induced apoptosis in MCL cells irrespective of TP53 status. Mechanistic studies reveal a striking dichotomy: in TP53 mutant cells, NAMPT inhibition triggers synthetic lethality through catastrophic DNA damage response (DDR) pathway disruption, whereas in TP53 wild-type cells, it selectively suppresses B-cell receptor (BCR) signaling and immune checkpoint activation. This biological divergence translates to clinically actionable synergies: TP53 mutant cells exhibit marked sensitization to alkylating agents and DDR-targeting therapies, whereas TP53 wild-type models show potential for overcoming BTK inhibitor resistance. In vivo studies confirm that NAMPT-based combinations achieve profound tumor regression in TP53 mutant xenografts without exacerbating toxicity. Our findings establish NAMPT as a dual-context therapeutic node, providing a precision medicine framework to circumvent chemoresistance in high-risk MCL. These results advocate for the clinical evaluation of TP53 status\u2013guided NAMPT inhibitor combinations to address this unmet oncologic challenge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016765","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T20:59:08Z","timestamp":1766437148000},"page":"1722-1732","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-2787","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"first","affiliation":[{"name":"1School of Life Sciences, Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Liaoning Normal University, Dalian, China"},{"name":"2Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8302-2577","authenticated-orcid":false,"given":"Yicen","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0163-5507","authenticated-orcid":false,"given":"Linna","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9591-5830","authenticated-orcid":false,"given":"Saisai","family":"Guo","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1018-4282","authenticated-orcid":false,"given":"Zhihao","family":"Wu","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6167-3319","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"5Tianjin Institutes of Health Science, Tianjin, China"},{"name":"6LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0976-0281","authenticated-orcid":false,"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7972-8461","authenticated-orcid":false,"given":"Jixia","family":"Kong","sequence":"additional","affiliation":[{"name":"7Department of Pathology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-6411","authenticated-orcid":false,"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-4697","authenticated-orcid":false,"given":"Kun","family":"Shao","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-8593","authenticated-orcid":false,"given":"Hong","family":"Yang","sequence":"additional","affiliation":[{"name":"1School of Life Sciences, Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Liaoning Normal University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"1","key":"2026030915463122200_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","article-title":"Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents","volume":"16","author":"Jain","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026030915463122200_bib2","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026030915463122200_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"issue":"26","key":"2026030915463122200_bib4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2026030915463122200_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ajh.27044","article-title":"Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy","volume":"98","author":"Karolov\u00e1","year":"2023","journal-title":"Am J Hematol"},{"key":"2026030915463122200_bib6","doi-asserted-by":"crossref","first-page":"102651","DOI":"10.1016\/j.ctrv.2023.102651","article-title":"Recent advances in genomics and therapeutics in mantle cell lymphoma","volume":"122","author":"Lu","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"2026030915463122200_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2026030915463122200_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD+ metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026030915463122200_bib9","doi-asserted-by":"crossref","first-page":"115607","DOI":"10.1016\/j.ejmech.2023.115607","article-title":"Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery","volume":"258","author":"Tang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"2026030915463122200_bib10","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fonc.2019.01514","article-title":"Beyond energy metabolism: exploiting the additional roles of NAMPT for cancer therapy","volume":"9","author":"Heske","year":"2019","journal-title":"Front Oncol"},{"issue":"23","key":"2026030915463122200_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.21037\/atm.2019.11.32","article-title":"Relationship between NAMPT\/PBEF\/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis","volume":"7","author":"Ji","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026030915463122200_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.semcdb.2019.05.001","article-title":"Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT)","volume":"98","author":"Audrito","year":"2020","journal-title":"Semin Cell Dev Biol"},{"issue":"12","key":"2026030915463122200_bib13","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1038\/s41375-023-02038-0","article-title":"Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function","volume":"37","author":"Zhang","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026030915463122200_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1078-0432.CCR-18-1776","article-title":"Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstr\u00f6m macroglobulinemia","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2026030915463122200_bib15","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2016-06-724831","article-title":"Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma","volume":"129","author":"Fulciniti","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026030915463122200_bib16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-019-0692-5","article-title":"OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis","volume":"34","author":"Korotchkina","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2026030915463122200_bib17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/s41375-019-0683-6","article-title":"Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia","volume":"34","author":"Somers","year":"2020","journal-title":"Leukemia"},{"issue":"45","key":"2026030915463122200_bib18","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026030915463122200_bib19","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2026030915463122200_bib20","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2026030915463122200_bib21","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"17","key":"2026030915463122200_bib22","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026030915463122200_bib23","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/bjh.17063","article-title":"A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma","volume":"191","author":"Obr","year":"2020","journal-title":"Br J Haematol"},{"issue":"4-5","key":"2026030915463122200_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1600-0463.2011.02733.x","article-title":"Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas","volume":"119","author":"Olesen","year":"2011","journal-title":"Apmis"},{"issue":"1","key":"2026030915463122200_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers14010160","article-title":"PAK4 and NAMPT as novel therapeutic targets in diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma","volume":"14","author":"Khan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2026030915463122200_bib26","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","article-title":"Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition","volume":"120","author":"Cea","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026030915463122200_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/bloodadvances.2024013425","article-title":"NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma","volume":"9","author":"Soncini","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026030915463122200_bib28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"key":"2026030915463122200_bib29","doi-asserted-by":"crossref","first-page":"172738","DOI":"10.1016\/j.ejphar.2019.172738","article-title":"High expression of NAMPT in adult T-cell leukemia\/lymphoma and anti-tumor activity of a NAMPT inhibitor","volume":"865","author":"Kozako","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"2026030915463122200_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc3342","article-title":"The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance","volume":"12","author":"Bouwman","year":"2012","journal-title":"Nat Rev Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1722\/2506448\/blooda_adv-2025-016765-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1722\/2506448\/blooda_adv-2025-016765-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:46:41Z","timestamp":1773085601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1722\/557446\/Inhibition-of-NAMPT-targets-DNA-damage-response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016765","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}